Lilly competitor Glaxo to shake up U.S. operations
A major drugmaker that was part of three-way multi-billion-dollar deal this year involving Eli Lilly and Co. is planning a reorganization that will include hundreds of job cuts in the United States.
Pharmaceutical
Articles
Fifth person pleads guilty in Lilly warehouse heist
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
New type of cholesterol drug shows promise in study
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
Eli Lilly donates $12.7 million to United Way
The donation represents the giving of employees and retirees of Lilly and Elanco Animal Health in the U.S. and Puerto Rico, plus a matching contribution from the Lilly Foundation.
Lilly partner accused of putting Actos profit ahead of safety
Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
Lilly to end development of lupus drug after trial failure
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
Obamacare enrollment at 7.3 million people, official says
That’s a 9-percent reduction from the government’s May estimate of 8 million, which reflected only how many people had signed up, not how many had paid and were enrolled in the coverage.
FDA approves Eli Lilly’s injectable diabetes drug
The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.
Testosterone drugs need study on heart risks, FDA panel says
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
FDA set to review testosterone-boosting drug usage
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Lilly cancer drug fares well in late-stage study
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Lilly receives European marketing OK for new insulin
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.
Lilly says new insulin fares better than rival’s in late-stage tests
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Lilly, partner lose appeal to overturn $9 billion Actos court award
Takeda Pharmaceutical Co. and Eli Lilly and Co. lost a bid to have a judge throw out a combined $9 billion punitive-damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
HQ move earns pharma firm another tax break
A Carmel-based institutional pharmacy plans to invest $8 million expanding its Noblesville operations, which include its headquarters. On Tuesday, it received its second tax-incentive deal from the city in two years.
Lilly wins tentative approval for diabetes drug
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
Cardinal Health unit seeks tax breaks for local drug facility
A subsidiary of Dublin, Ohio-based Cardinal Health Inc. is seeking tax breaks from the city of Indianapolis to help it open a $14.4 million local drug-production facility that would employ 85 workers by 2017.
Biotech comeback: Eli Lilly making renewed push in lucrative field it once pioneered
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Indy startup has rare disease in its sights
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.